Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

mRNA influenza vaccine - Sanofi/Translate Bio

X
Drug Profile

mRNA influenza vaccine - Sanofi/Translate Bio

Alternative Names: Messenger RNA influenza vaccine - Sanofi/Translate Bio; mRNA NA vaccine; mRNA-based influenza vaccine - Sanofi/Translate Bio; MRT-5400; MRT-5401; Seasonal mRNA flu vaccine - Sanofi/Translate Bio; Seasonal mRNA influenza vaccine - Sanofi/Translate Bio

Latest Information Update: 13 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi Pasteur; Translate Bio
  • Developer Sanofi; Translate Bio
  • Class Influenza virus vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Influenza virus infections

Most Recent Events

  • 13 Feb 2024 Sanofi Pasteur completes a phase I trial for Influenza virus infections (Prevention) in USA (IM) (NCT05426174)
  • 07 Nov 2023 mRNA influenza vaccine is still in phase-I trials for Influenza virus infections (Prevention) in USA (IM) (Sanofi pipeline; February 2023)
  • 07 Nov 2023 mRNA influenza vaccine is still in preclinical trial for Influenza virus infections (Prevention) in France (IM) (Sanofi pipeline; February 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top